[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Prince of Songkla University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":218},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,48,79,104,134,163,189],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100647955","effectiveness-of-mitragynine-topical-patch-for-pain-reduction-in-myofascial-pain-syndrome-100647955",false,"NCT07713771","Effectiveness of Mitragynine Topical Patch for Pain Reduction in Myofascial Pain Syndrome","Effectiveness of Mitragynine Topical Patch From Kratom for Pain Reduction in Myofascial Pain Syndrome of Upper Trapezius Muscle: Double Blinded Placebo, Randomized Controlled Trial","mirtapatch","Inclusion Criteria:\n\n* \\- Patients aged 18-50 years.\n* Experiencing neck or shoulder pain for more than 3 months.\n* Diagnosed with myofascial pain syndrome, with the most tender trigger point located in the upper trapezius muscle and a pain score between 30-60 mm measured using the Visual Analogue Scale (VAS).\n\nExclusion Criteria:\n\n* \\- History of other neck-related conditions (e.g., whiplash injury, cervical radiculopathy, fibromyalgia syndrome, cervical spine surgery and\u002For fracture).\n* History of systemic diseases (e.g., rheumatism, multiple sclerosis, cervical myelopathy), hepatitis, liver failure, or kidney disease (serum creatinine \\> 2.0 mg\u002FdL).\n* Symptoms or conditions contraindicating the use of patches, such as wounds or infections at the painful site.\n* History of allergy to paracetamol or kratom.\n* History of allergy to adhesive patches\u002Fplasters.\n* Pregnant or breastfeeding women.\n* Receipt of treatment with analgesics other than paracetamol, physical therapy, dry needling\u002Facupuncture, massage, or topical medications within the previous week.\n* Individuals who are unable to read or write.","ALL","18 Years","50 Years",{"count":21,"type":22},64,"ESTIMATED","INTERVENTIONAL",[25],"PHASE3","Myofascial Pain Syndrome (MPS) is one of the leading causes of both acute and chronic musculoskeletal pain encountered in clinical practice.¹ The most common presentation is low back pain, followed by pain in the neck and scapular regions.² These symptoms significantly affect quality of life and work performance. A common site involved in neck pain syndrome is the trapezius muscle, which may cause pain in the shoulder, neck, and occipital region. In some patients, neurological symptoms such as goosebumps or dizziness may also occur.³ Pain can occur in individuals of all age groups and may be either acute or chronic. It can arise from injuries or various diseases. Pain may result from different pathologies, including nociceptive pain, neuropathic pain, or a combination of both. Current medical treatment guidelines include both conventional medications and herbal extract-based therapies. In the 2022 National List of Essential Herbal Medicines of Thailand, several herbal formulations are indicated for pain relief. Oral preparations include Khasai Sen, Thorani Sandhakhat, and Ya Phasom Thao Wan Priang, while topical preparations include chili-based formulations, plai preparations, and plai oil. These remedies are indicated for the relief of body aches and muscle pain.⁶ Kratom, or \\*Mitragyna speciosa\\* (Korth.) Havil., is a plant belonging to the Rubiaceae family. In southern Thailand, it is commonly known as \"Thom.\" Kratom leaves contain a variety of chemical constituents, including alkaloids, flavonoids, triterpenes, and phenolic compounds. Among these, indole alkaloids represent the major group. The principal active compound is mitragynine, which accounts for approximately two-thirds of the total alkaloid content, or about 66% by weight.⁷ Pharmacologically, orally administered mitragynine affects both the autonomic and central nervous systems. It possesses analgesic properties through binding to opioid receptors. Additionally, it reduces pain signal transmission to the brain via the noradrenergic and serotonergic systems.⁸ The mitragynine pain-relief patch used in this study is a product containing kratom extract formulated to deliver 10 milligrams of mitragynine per patch. It is designed as a topical patch, allowing the active ingredient to be absorbed into the outer layers of the skin without entering the bloodstream.¹¹ The patch consists of sodium alginate, pectin, and agar, which are naturally derived polymers commonly used as pharmaceutical excipients. The hypothesis of this study is that this locally acting \"mitragynine pain-relief patch\" can reduce pain and inflammation through the TRPV1 receptor mechanism described above.\n\nNeck, shoulder, and upper back pain are among the most common reasons patients attend general practice, orthopedic, and rehabilitation clinics. Patients with chronic myofascial pain syndrome (defined as pain persisting for more than three months) may be treated using various approaches depending on symptom severity, accessibility of services, and individual suitability. These approaches include oral medications, topical agents, local injections, acupuncture, physical therapy, and muscle stretching exercises.\n\nMany patients may have contraindications to oral medications, acupuncture, or regular attendance at physical therapy sessions, which can negatively affect their overall quality of life. Currently, topical medications are commonly prescribed for these patients at Hospital; however, treatment outcomes are often suboptimal. Moreover, most topical preparations produce a warming effect and may easily cause skin irritation, particularly in elderly patients with fragile skin. If the mitragynine pain-relief patch demonstrates effective pain reduction, it may be further developed as an alternative treatment option for these patients.\n\nThe objective of this study is to evaluate the efficacy of a mitragynine-containing kratom pain-relief patch in patients with myofascial pain syndrome, compared with a placebo patch (a patch containing only the base formulation without kratom extract), and to determine whether there is a difference in pain-relief response between the two groups and, if so, how that difference manifests.",[28,29],"Topical Analgesia","Myofascial Pain Syndrome - Neck",[31,32,33,34],"mirtagynine","kratom patch","topical patch","pain reduction","NOT_YET_RECRUITING","2026-08-05",{"date":38,"type":39},"2026-08-10","ACTUAL",{"date":41,"type":22},"2026-10-01",{"date":43,"type":22},"2029-10-31",{"name":45,"class":46},"Prince of Songkla University","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":56,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":23,"phases":59,"briefSummary":61,"conditions":62,"keywords":65,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":47},"100638223","hand-versus-foot-controls-for-robotic-surgery-simulation-100638223","NCT07618429","Hand Versus Foot Controls for Robotic Surgery Simulation","Control Location Using Two Commands: Hand Versus Foot, Workload and Accuracy Response Trial: A Randomized Controlled Trial in Robotic Surgery Simulation","CLUTCH WAR","Inclusion Criteria:\n\n* Active surgical trainees (residents or fellows) currently enrolled in a recognized surgical specialty program, including general surgery, obstetrics and gynecology, urology, cardiothoracic surgery or pediatric surgery, at Prince of Songkla University\n* Complete absence of prior hands-on experience performing clinical robotic surgery or undergoing formalized robotic simulator training\n\nExclusion Criteria:\n\n* Pre-existing physical, orthopedic, or neurological conditions that impair standard motor function of the upper or lower limbs, including active movement disorders or motor control deficits capable of confounding objective simulation performance metrics.",true,{"count":58,"type":22},86,[60],"NA","Why is the study being done? Robotic-assisted surgery offers high precision and ergonomic benefits, but it requires specialized console skills that differ significantly from traditional open or laparoscopic surgery. A fundamental part of operating a robotic surgical system is clutch control, which allows surgeons to reposition their controllers without moving the actual surgical instruments. Inefficient clutching can disrupt workflow, increase mental workload, and lead to operator fatigue.\n\nModern platforms like the Da Vinci Xi offer two main options for clutching: hand-controlled clutching and foot-controlled clutching. Currently, there is limited research isolating how these different clutch options affect performance, especially for novice operators who have no prior robotic experience. This study aims to evaluate and compare hand clutch versus foot clutch methods to determine which approach better supports efficient skill acquisition, precision, and comfort for beginners.\n\nWhat happens during the study? Surgical trainees with no prior robotic surgery experience will be recruited for this study. After completing an initial baseline questionnaire and receiving a standardized orientation on the equipment, all participants will undergo a 20-minute practice session where they get to try both hand and foot clutching mechanisms.\n\nOne week after the practice session, participants will return for the formal evaluation and be randomly assigned to one of two groups:\n\n1. Hand Clutch Group: Participants will complete a standardized simulation task using only the hand clutch button.\n2. Foot Clutch Group: Participants will complete the exact same simulation task using only the foot clutch pedal.\n\nThe simulator automatically tracks performance metrics such as task completion time, movement efficiency, instrument collisions, and technical errors. Immediately following the test, participants will fill out a short survey rating their satisfaction, comfort, and the learning difficulty of their assigned clutch method.",[63,64],"No Disease or Condition is Being Studied","Surgical Procedures, Minimally Invasive",[66,67,68,69,70],"Robotic surgery","Surgical simulation","Psychomotor skill acquisition","Technical performance metrics","Randomized controlled trial","2026-05-29",{"date":73,"type":39},"2026-06-02",{"date":75,"type":22},"2026-06-15",{"date":77,"type":22},"2026-10-31",{"name":45,"class":46},{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":23,"phases":88,"briefSummary":89,"conditions":90,"keywords":93,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":47},"100335545","intracameral-versus-intravitreal-bevacizumab-injection-in-nvg-rct-100335545","NCT03648814","Intracameral Versus Intravitreal Bevacizumab Injection in NVG: RCT","Efficacy and Safety of Intracameral Versus Intravitreal Bevacizumab Injection as an Adjunctive Therapy Before Trabeculectomy With Mitomycin-C in Neovascular Glaucoma: A Prospective Randomized Trial","Inclusion Criteria:\n\n1. Diagnosis of neovascular glaucoma\n2. The patients having IOP \\> 21 mmHg, having the indication for trabeculectomy\n3. The patients' age of at least 18-year-old\n4. The patients having visual potential at least hand motion.\n5. Present of NVI or NVA.\n6. Willing and able to provide informed consent to participate in the study\n7. Able to understand the purpose of the study, his\u002Fher role, and is available to return to the clinic\u002Fhospital for all required follow-up visits\n\nExclusion Criteria:\n\n1. One eye patient\n2. Patients having severe corneal edema or total hyphema obscure NVI or NVA view.\n3. Cannot obtain endothelial cell count.\n4. History of bevacizumab or fluorescence dye allergy.\n5. Active infectious ocular disease including endophthalmitis and corneal ulcer\n6. History of systemic disease including ischemic heart disease, cerebrovascular disease, end-stage renal disease, liver failure, uncontrolled hypertension\n7. Has or planning to be pregnant or breastfeeding",{"count":87,"type":22},40,[60],"To prospect studying the efficacy and safety of treating NVG with the intracameral versus the intravitreal injection of Bevacizumab.",[91,92],"Glaucoma, Neovascular","Vascular Endothelial Growth Factor Overexpression",[94],"Neovascular glaucoma","RECRUITING","2025-08-15",{"date":98,"type":39},"2025-08-21",{"date":100,"type":39},"2018-08-01",{"date":102,"type":22},"2026-07-01",{"name":45,"class":46},{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":110,"eligibilityCriteria":111,"healthyVolunteers":56,"sex":17,"minAge":112,"maxAge":113,"enrollmentInfo":114,"targetDuration":4,"studyType":23,"phases":116,"briefSummary":117,"conditions":118,"keywords":120,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":133},"100580732","chinese-art-activities-or-combined-with-peer-group-participation-on-psychological-well-being-100580732","NCT06841133","Chinese Art Activities or Combined With Peer Group Participation on Psychological Well Being","The Effectiveness of Chinese Art Activities Combined With Peer Group Participation on Psychological Well Being Among Newly Old Chinese of Elderly Center: Randomized Controlled Trail","CAA+PGP#PWB","Inclusion Criteria:\n\n* Age 60-85 years.\n* Older persons living in Elderly Centers (ECs) for the first time, with a duration of stay ≤1 year.\n* Normal cognitive function (Mini-Mental State Examination \\[MMSE\\] score \\>24).\n* Possess necessary reading and writing skills.\n* Volunteer to participate in the study.\n\nExclusion Criteria:\n\n* Older persons with serious diseases (e.g., heart failure, asthma, cerebrovascular disease, advanced tumors).\n* Older persons who later leave the elderly center.","60 Years","85 Years",{"count":115,"type":22},90,[60],"The goal of this trial is to evaluate the effects of two interventions : routine care plus Chinese Art Activities(+CAA) and routine care plus Chinese Art Activities combined with Peer Group Participation (+CAA+PGP) on psychological well-being, loneliness, happiness, relaxation, and salivary cortisol levels in elderly participants (aged 60-85, new residents with ≤1 year of stay). The main questions it aims to answer are:\n\n* Does the +CAA intervention improve psychological well-being and related outcomes compared to routine care?\n* Does the +CAA+PGP intervention provide additional benefits over +CAA alone? Researchers will compare three groups (Group A: +CAA, Group B: +CAA +PGP, Group C: routine care) to see if the interventions lead to immediate and sustained improvements in the measured outcomes.\n\nParticipants will:\n\n* Undergo baseline assessments of psychological well-being(PWB), loneliness, happiness, relaxation, and salivary cortisol levels.\n* Receive their assigned intervention over three sessions within one week (Monday, Wednesday, Friday).\n* Complete outcome measures 30 minutes before and after each session.\n* Participate in a final follow-up assessment one week after the last session to evaluate sustained effects.",[119],"Aging",[121,122,123,124],"Art Activity","Peer Group","psychological well-being","older","2025-07-01",{"date":127,"type":39},"2025-07-03",{"date":129,"type":22},"2025-07-09",{"date":131,"type":22},"2025-08-09",{"name":45,"class":46},3,{"id":135,"slug":136,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":4,"eligibilityCriteria":140,"healthyVolunteers":11,"sex":17,"minAge":141,"maxAge":142,"enrollmentInfo":143,"targetDuration":4,"studyType":23,"phases":145,"briefSummary":146,"conditions":147,"keywords":149,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":47},"100544377","short-effects-of-simt-and-em-in-prolonged-mechanically-ventilated-patients-100544377","NCT06368089","Short Effects of SIMT and EM in Prolonged Mechanically Ventilated Patients","Short Effects of Speci|c Inspiratory Muscle Training and Early Mobilization in Prolonged Mechanically Ventilated Patients","Inclusion Criteria:\n\n* Patients with respiratory diseases who have been on mechanical ventilation for more than 48 hours and are ready to be weaned off or undergoing weaning trials with continuous positive airway pressure (CPAP) or synchronized intermittent mandatory ventilation (SIMV).\n* The PaO2\u002FFiO2 ratio is ≥ 150-200, with FiO2 ≤ 0.4-0.5 and PEEP ≤ 5-8 cmH2O, and a pH \\> 7.3 in blood plasma.\n* The age range is between 40 and 80 years old.\n* Patients exhibit good self-awareness and cooperation in training (Riker score of 4).\n* They can understand and communicate in Thai\n\nExclusion Criteria:\n\n* Clinical instability (HR \\> 120 beats\u002Fminute, RR \\> 30 breaths\u002Fminute, SatO2 \\< 90%, SBP \\> 140 mmHg or \\< 90 mmHg)\n* Patients who can be extubated and use non-invasive ventilation only or successfully extubated within the first 24 hours.\n* Patients with altered mental status (Glasgow Coma Score \\< 10) and inability to cooperate with training (Riker score \\< 4 or \\> 4)\n* Patients with limitations or contraindications such as inability to adjust the bed to a 45-degree angle or sit on the side of the bed, such as those with spinal cord injuries or recent head surgeries.\n* History of hemoptysis, pneumothorax\n* History of neuromuscular diseases causing muscle weakness and decreased sensation.\n* Patients with excessive cardiac stimulation (\\> 5 micrograms per kilogram per minute)\n* Heart rate \\> 140 beats per minute\n* Hemoglobin levels \\< 8-10 grams per deciliter\n* Patients with difficult airway issues.","40 Years","80 Years",{"count":144,"type":22},46,[60],"Using mechanical ventilation for more than 18 hours can affect respiratory muscle and postural muscle control, making it difficult to wean off the ventilator and reducing mobility. The aim of this study is to:\n\n1. Compare the effects of respiratory muscle strength training and early mobilization on dynamic lung compliance and maximum inspiratory pressure before and after a 7-day training period.\n2. Compare the success rate of weaning and the duration of weaning between the respiratory muscle strength training and the early mobilization program.",[148],"Ventilator Dependent",[150,151,152,153,154],"Specific inspiratory muscle training","Early mobilization","Lung compliance","Prolong mechanical ventilation","Weaning outcome","2024-11-04",{"date":157,"type":39},"2024-11-06",{"date":159,"type":39},"2024-05-06",{"date":161,"type":22},"2026-03",{"name":45,"class":46},{"id":164,"slug":165,"hasResults":11,"nctId":166,"briefTitle":167,"officialTitle":168,"acronym":169,"eligibilityCriteria":170,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":171,"targetDuration":4,"studyType":23,"phases":173,"briefSummary":174,"conditions":175,"keywords":176,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":182,"startDateStruct":184,"completionDateStruct":186,"leadSponsor":188,"locationsCount":47},"100536518","specific-versus-empirical-anthelminthic-treatment-in-eosinophilia-100536518","NCT06265870","Specific Versus Empirical Anthelminthic Treatment in Eosinophilia","Comparison of Outcome Between Specific Anthelminthic Treatment According to Test Results and Empirical Anthelminthic Treatment in Eosinophilic Patient","Eosinophilia","Inclusion Criteria:\n\n* Participants who come for check-ups at general practitioner, primary care unit, and Srivejchavat Premium Center have an absolute eosinophil count greater than 500 cells\u002Fmicroliter with a white blood cell count less than 10,000 cells\u002Fmicroliter.\n* Age at least 18 years old\n* Consent to participate in research\n\nExclusion Criteria:\n\n* Having any characteristics that need urgent care 1.1 Having history of unintended significant weight loss is defined as the loss of body weight exceeding 10% within a span of six months without deliberate attention.\n\n1.2 Physical examination revealed a body temperature equal to or greater than 37.8 degrees Celsius, lymphadenopathy or hepatosplenomegaly.\n\n1.3 CBC revealed blast cell\n\n* Receiving anthelminthic drug within 6 months\n* Underlying cancer (active stage), HIV, HBV, HCV, collagen vascular disease, active TB\n* Allergy to albendazole, ivermectin, or metronidazole\n* Pregnancy or lactation\n* Serum transaminase higher than 2 times of upper normal limit\n* Taking medications that may induce eosinophilia within the past three months, such as herbal supplements, NSAIDs, Salicylic acid, Carbamazepine, Colchicine, Nitrofurantoin, Dapsone, or Minocycline, was reported.",{"count":172,"type":22},700,[60],"There are a few guidelines recommend about management of eosinophilia worldwide, most of guielines recommend a thorough history-taking and physical examination. Subsequently, investigations are requested based on suspected causes. In cases where parasite infection is suspected, particularly in developing countries, stool microscopy and serology are recommended. However, limitations such as low sensitivity of stool microscopy, the inconvenience of collecting multiple stool samples, and the high cost and unavailability of serology may arise. Consequently, some physicians opt for empiric anthelminthic regimens in managing eosinophilic patients, even without stool tests or if stool test results are normal. If subsequent complete blood count (CBC) results show a recovery of absolute eosinophil count, it is assumed that eosinophilia was caused by a parasite infection. While some studies demonstrate the efficacy and simplicity of this approach, there is a risk of overestimating parasite infection in eosinophilic patients, potential adverse drug reactions from unnecessary anthelminthic treatment, and the possibility of drug resistance due to inappropriate dosing. To address this gap, no study has yet compared the efficacy between specific anthelminthic treatment based on test results and empirical anthelminthic treatment in eosinophilic patients. Therefore, the investigators are conducting this study.",[169],[177,178,179,180],"eosinophilia","anthelminthic drugs","empirical treatment","stool examination","2024-09-22",{"date":183,"type":39},"2024-09-24",{"date":185,"type":39},"2024-05-01",{"date":187,"type":22},"2025-12-31",{"name":45,"class":46},{"id":190,"slug":191,"hasResults":11,"nctId":192,"briefTitle":193,"officialTitle":194,"acronym":195,"eligibilityCriteria":196,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":197,"targetDuration":4,"studyType":23,"phases":199,"briefSummary":200,"conditions":201,"keywords":204,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":210,"lastUpdatePostDateStruct":211,"startDateStruct":213,"completionDateStruct":215,"leadSponsor":217,"locationsCount":47},"100532954","higher-and-standard-doses-of-enteral-zinc-supplementation-in-very-preterm-infants-100532954","NCT06219525","Higher and Standard Doses of Enteral Zinc Supplementation in Very Preterm Infants","Higher and Standard Doses of Enteral Zinc Supplementation in Very Preterm Infants: A Randomized Controlled Trial","ZnVeryPT","Inclusion Criteria:\n\n* Very preterm neonates (gestational age \\[GA\\]: 24 0\u002F7-32 6\u002F7 weeks and BW: 401-1800 grams) were consecutively admitted in the NICU and NMCU\n* Body weight at enrollment less than 800 grams\n* Stable neonates and full enteral feeding (150 mL\u002Fkg\u002Fday) at least for a few days\n\nExclusion Criteria:\n\n* Outborn neonate who was admitted in study center after 7 days of life\n* Congenital infections\n* Malformations, syndromes, or genetic defects\n* Evidence of culture proven sepsis or necrotizing enterocolitis or death diagnosed before enrollment\n* Gastrointestinal (GI) surgery or high GI fluid output (usually ileostomy losses)\n* Unstable neonate during weighing including on intercostal drainage tube or drainage\n* Neonates need diuretics more than 7 days\n* Severe birth asphyxia (5-minute Apgar score less than 4)\n* Parents' decision not to participate the study",{"count":198,"type":22},120,[60],"The goal of this randomized clinical trial is to compare the effect of higher (10 mg per day) versus standard (1 mg per day) doses of zinc supplementation The main questions it aims to answer are:\n\n* Growth velocities and delta z-scores during the date of start intervention until the end of the time interval (at least 2 weeks of intervention on date of 44 weeks of postmenstrual age or discharge whichever came first) in very preterm infants with a birthweight less than1800 grams.\n* Growth and neurodevelopment at 24 months postnatal age",[202,203],"Very Preterm Infants","Zinc Deficiency",[205,206,207,208,209],"Growth and Development","Mortality","Newborn","Premature Infant","Zinc","2024-09-14",{"date":212,"type":39},"2024-09-19",{"date":214,"type":39},"2024-04-02",{"date":216,"type":22},"2027-12-31",{"name":45,"class":46},""]